{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:50:49Z","timestamp":1777542649496,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.urolonc.2020.06.031","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T01:55:28Z","timestamp":1595469328000},"page":"850.e9-850.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure"],"prefix":"10.1016","volume":"38","author":[{"given":"Tristan","family":"Juvet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Lajkosz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher JD","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Kuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Erlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lior","family":"Krimus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil E.","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish S","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre R.","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.urolonc.2020.06.031_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2018.06.024","article-title":"Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations","volume":"74","author":"Klaassen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.06.031_bib0002","unstructured":"FDA Draft Guidance. BCG-Unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. Last accessed November 13, 2018. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM529600.pdf"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.031_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2020.06.031_bib0004","first-page":"875","article-title":"Electromotive delivery of mitomycin C into human bladder wall","volume":"57","author":"Di Stasi","year":"1997","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.031_bib0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.06.031_bib0006","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000502663","article-title":"Intravesical treatment with electro-mediated administration of Mytomycin C as prophylaxis for intermediate and high-risk nonmuscle-invasive bladder cancer: a retrospective multicenter study","volume":"103","author":"Carando","year":"2019","journal-title":"Uro Int"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.031_bib0007","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2020.06.031_bib0008","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration. February 2018. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. (https:\/\/www.fda.gov\/media\/101468\/download)."},{"issue":"8","key":"10.1016\/j.urolonc.2020.06.031_bib0009","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication or to or failure after bacillus Calmette-Gu\u00e9rin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.06.031_bib0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1756287214541798","article-title":"Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder","volume":"6","author":"Cookson","year":"2014","journal-title":"Ther Adv Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.06.031_bib0011","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Gu\u00e9rin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"issue":"16","key":"10.1016\/j.urolonc.2020.06.031_bib0012","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.06.031_bib0013","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.juro.2016.01.103","article-title":"Sequential bacillus Calmette-Gu\u00e9rin\/electromotive drug administration of mitomycin C as the standard intravesical regimen in high risk nonmuscle invasive bladder cancer: 2-year outcomes","volume":"195","author":"Gan","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.06.031_bib0014","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.06.031_bib0015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","article-title":"Hyperthermic intravesical chemotherapy (HIVEC\u00ae) in BCG unresponsive NMIBC patients","volume":"4","author":"de Jong","year":"2018","journal-title":"Bladder Cancer"},{"issue":"38","key":"10.1016\/j.urolonc.2020.06.031_bib0016","first-page":"1","article-title":"Experience with sequential intravesical gemcitabine and docetaxel as salvage therapy for non-muscle invasive bladder cancer","volume":"17","author":"Velaer","year":"2016","journal-title":"Curr Urol Rep"},{"issue":"3","key":"10.1016\/j.urolonc.2020.06.031_bib0017","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Longterm survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette\u2013Gu\u00e9rin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.06.031_bib0018","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.juro.2014.06.084","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette\u2013Guerin treatment failure","volume":"192","author":"Mckiernan","year":"2014","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.06.031_bib0019","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu\u00e9rin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.06.031_bib0020","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.06.031_bib0021","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","article-title":"Efficacy of mycobacterium Phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients","volume":"3","author":"Li","year":"2017","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2020.06.031_bib0022","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"30","key":"10.1016\/j.urolonc.2020.06.031_bib0023","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFN?\/Syn3 for patients with high-grade, bacillus calmette-guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.06.031_bib0024","doi-asserted-by":"crossref","unstructured":"Bachir BG, Dragomir A, Aprikian A, et al. Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Gu\u00e9rin and electromotive mitomycin versus bacillus Calmette-Gu\u00e9rin alone for patients with high-risk non-muscle-invasive bladder cancer2014;120(16):2424-31.","DOI":"10.1002\/cncr.28731"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:20:10Z","timestamp":1761042010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920303185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1078143920303185"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.031","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}